Skip to main content

Market Overview

MediWound: Q3 Earnings Insights

Share:

 

Shares of MediWound (NASDAQ:MDWD) remained unaffected after the company reported Q3 results.

Quarterly Results

Earnings per share rose 36.36% over the past year to ($0.07), which beat the estimate of ($0.10).

Revenue of $6,625,000 higher by 28.89% year over year, which beat the estimate of $5,790,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Nov 10, 2020

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/nod4bwun

Price Action

Company's 52-week high was at $4.44

52-week low: $1.44

Price action over last quarter: down 1.79%

Company Description

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. Its first biopharmaceutical product, NexoBrid removes dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. NexoBrid is currently in clinical development in North America and is in the process of preparing its Biologics License Application. The company derives its revenue from United States.

 

Related Articles (MDWD)

View Comments and Join the Discussion!

Posted-In: Earnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com